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Abstract Substance abuse is the most prevalent comor-
bid psychiatric condition associated with schizophrenia,
and cannabis is the illicit drug most often abused. Apart
from worsening the course of schizophrenia, frequent
cannabis use especially at an early age seems to be an
important risk factor for developing schizophrenia.
Although a large body of neuroimaging studies gives evi-
dence for structural alterations in many different brain
regions in schizophrenia patients, there is still limited
knowledge of the impact of cannabis abuse on brain
structure in schizophrenia. We performed a systematic
review including structural magnetic resonance imaging
studies comparing high-risk and schizophrenia patients
with and without cannabis abuse and found inconclusive
results. While there is some evidence that chronic cannabis
abuse could alter brain morphology in schizophrenia in
patients continuing their cannabis consumption, there is no
convincing evidence that this alteration takes place before
the onset of schizophrenia when looking at first-episode
patients. There is some weak evidence that cannabis abuse
could affect brain structures in high-risk subjects, but
replication of these studies is needed.
Keywords Cannabis  Substance abuse  Magnetic
resonance imaging  Schizophrenia  High-risk subjects 
First-episode patients
Introduction
Substance abuse in individuals with schizophrenia is very
common; it has become the most prevalent comorbid psy-
chiatric condition associated with schizophrenia and con-
tributes to an unfavourable disease course [65]. Apart from
the legal substances such as tobacco and alcohol, cannabis
is the most illicit drug abused in schizophrenia patients.
Depending on the study, the comorbidity rates are within a
range from approximately 15 to 65 % [8, 37]. In a popu-
lation-based study, the prevalence of substance use disorder
in patients with schizophrenia was estimated to be 4.6 times
higher than in the general population [46]. Substance abuse,
especially cannabis, has also been discussed as an important
risk factor for developing schizophrenia [34]. At least
substance abuse may contribute to an earlier onset of
schizophrenia as seen in many first-episode studies [6].
Persisting comorbid substance abuse is associated with
negative outcome in schizophrenia, including more fre-
quent and longer periods of hospitalization, higher relapse
rates even in first-episode patients, elevated rates of
extrapyramidal motor symptoms (EPS), lower medication
compliance, higher rates of unemployment, violence,
higher rate of criminality and an increased risk of com-
mitting suicide [10, 23, 28, 31, 45, 49, 54, 56]. Hypotheses
explaining the possible aetiological relationship between
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the two disorders describe concepts of common increased
vulnerability to both disorders with regard to dysfunctional
affect regulation or deficits with stress coping, of secondary
substance abuse (in the context of self-medication or
increased sensitivity to drug effects), of secondary psy-
chotic disorder triggered or induced by substance use and
of a bidirectional maintenance of both disorders by
neurobiological or psychological interaction [16, 36]. The
effects of abused substances on schizophrenia symptoms
vary, making it difficult to differentiate between substance
abuse–related symptoms and those related to functional
psychosis [16]. For example, alcoholic hallucinosis shares
some features with paranoid schizophrenia, and the dif-
ferentiation of both diseases may be difficult [55].
Differences in psychopathology between schizophrenia
patients with and without substance abuse were reported
inconsistently in the recent literature. Comorbid substance
abuse has been associated with higher positive symptom-
atology [6, 9, 53], lower negative symptoms [4, 39, 53],
fewer positive and negative symptoms [13] and no signif-
icant differences in psychopathology at admission and
follow-up [67].
Brain abnormalities identified in schizophrenia using
neuroimaging techniques reveal evidence for structural and
functional alterations in multiple brain regions focussing
on frontal cortex, temporal cortex, thalamus, hippocampal
complex, basal ganglia and even cerebellum [1]. Meta-
analyses and reviews of published studies concerning
volumetric measurements obtained by magnetic resonance
imaging have demonstrated ventricular enlargement and
volume decrease especially of frontal and temporal lobe
structures in schizophrenia [14, 18, 50, 68]. A meta-anal-
ysis of volumetric structural MRI studies investigating the
hippocampus reported a 4 % bilateral volume reduction in
schizophrenic patients [38], while some studies observed
pronounced decrease in hippocampal structures only on the
left side [51]. Abnormalities of temporal lobe structures
linked to mesolimbic system were suggested as responsible
for cognitive and emotional disturbance commonly seen in
schizophrenia, and temporal volume reductions have been
linked to clinical features. Especially reduced bilateral
hippocampal size has been associated with memory defi-
cits, and the decrease in total volume of superior temporal
gyrus (STG) correlates with the severity of thought disor-
der and auditory hallucinations [3, 51].
In first-episode and antipsychotic-naı¨ve patients, results
of volumetric MRI studies are inconclusive [59]. Ventric-
ular enlargement in antipsychotic-naive patients up to
20 % compared to healthy controls has been observed in
most studies, but volume changes of cerebral structures are
less conclusive. While most studies failed to detect a vol-
ume reduction in basal ganglia [59], a decreased thalamus
volume was frequently reported (in the range of 5 –18 % of
thalamus volume compared to healthy controls) [15, 19,
20]. Additionally, grey matter of frontal and temporal lobe
structures, in particular of the entorhinal cortex and the
hippocampus, was found to be reduced [21, 27, 57].
There is still limited knowledge about the influence of
substance abuse on brain morphology in schizophrenia
patients. In summary, the unfavourable effect of cannabis
abuse on the course of schizophrenia and the link between
cerebral volume loss and poor outcome in schizophrenia,
and a negative effect of substance abuse on brain volumes
in schizophrenia patients can be hypothesized. This review
focusses on the question whether comorbid patients do
show more structural cerebral changes than patients with-
out ongoing or previous cannabis abuse or not.
Methods
Search strategy, data sources and study selection
To achieve a comprehensive overview of the available neu-
roimaging studies dealing with our topic (structural volu-
metric measurement by MRI in schizophrenia patients with
comorbid cannabis abuse), a systematic literature search and
study evaluation were performed according to the Cochrane-
Criteria, using the computerized search databases PubMed
(1966–2012) and the Web Of Knowledge. Only studies
published in English language were considered for this
review. The keywords used were ‘‘schizophrenia’’ or ‘‘psy-
chosis’’, ‘‘sMRI’’ or ‘‘structural imaging’’ and ‘‘cannabis’’ or
‘‘marihuana’’ or ‘‘marijuana’’ or ‘‘tetrahydrocannabinol’’.
The search was limited to ‘‘humans’’. The literature obtained
from the search was carefully screened, based on the title and
abstract by two independent researchers. Only the appropri-
ate articles were selected, their full text was reviewed, and the
study outcomes were critically evaluated. The reference lists
of these articles were checked for relevant studies on the field
that were overlooked by the initial literature search.
Results
We found 105 hits in the databases, and after evaluating the
abstracts, we could include 16 studies covering our topic in
the review. The studies with their results are summarized in
the Tables 1, 2 and 3.
Volumetric sMRI studies in schizophrenia
(not first-episode) with comorbid cannabis abuse
Surprisingly, we could not identify MRI studies including
patients with chronic schizophrenia or a disease course
with multiple episodes and solely cannabis abuse.
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Table 1 Overview of structural magnetic resonance imaging studies in first-episode (FES) or early-onset (EOS) schizophrenia and comorbid
cannabis abuse
Study Methods Design Participants Findings
Cahn et al.
[7]





(N = 27) and without (N = 20)
cannabis abuse
No difference in volumes of total
white or grey matter, cerebellum
and caudate; reduced asymmetry










(N = 20) and without (N = 31)
cannabis abuse and healthy
controls (N = 56)
Cannabis abuse is associated with
less anterior cingulate grey
matter; no grey matter volume




sMRI, 1.5 Tesla, 1.5 mm thickness;
VBM, a priori single mask
consisting of hypothesized CB1-







(N = 15) and without (N = 24)
abuse and healthy controls
(N = 42)
Decrease in grey matter density in










(N = 19) and without (N = 32)
Cannabis abuse and healthy
controls (N = 31)
No morphological difference
between the two groups at the
beginning of the study at five-year
follow-up SZ-SUD shows more
pronounced brain volume
reduction and larger increase in







Male ROS (N = 35) with and
without a history of cannabis use
before the age of 17, matched HC
(N = 17)
ROS with cannabis use before the
age of 17 showed increased
directional coherence in the
bilateral uncinate fasciculus,
anterior internal capsule and
frontal white matter. These
abnormalities were absent in FOS










onset psychosis) with (N = 20)
and without (N = 21) substance
abuse (essentially Cannabis
abuse)
No differences in the assessed
temporolimbic brain morphology
(superior temporal gyrus (STG),
amygdala–hippocampus complex







EOS with regular use of cannabis
before the age of 15 (N = 10),
EOS with regular use of cannabis
at the age of 17 years or later
(N = 8), EOS who were cannabis
naı¨ve (N = 8), HC (N = 10)
Cannabis-naı¨ve EOS showed
reduced white matter density and
reduced fractional anisotropy in
the splenium of the corpus
callosum compared with EOS
with early-onset cannabis use. In
the same brain area, cannabis-










ROS (N = 51) and HC (N = 31),
5-year follow-up: N = 19 ROS
with cannabis abuse, N = 32
without cannabis abuse
Thinning of right supplementary
motor cortex, inferior frontal
cortex, superior temporal gyrus,
angular gyrus, occipital and
parietal lobe compared to
controls, compared to ROS
without cannabis abuse thinning
of left DLPFC, left ACC and left
occipital lobe demonstrated
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A MRI study including 17 patients with schizophrenia
(mean illness duration, above 2 years) and 31 healthy
controls with 48 % of the healthy group and 47 % of the
patients being long-term heavy cannabis users was per-
formed focussing on the cerebellum [52]. In cannabis users
with and without schizophrenia, cerebellar white matter
volume was reduced compared to healthy non-users, by
29.7 and 23.9 %, respectively, and by 17.7 % in patients
without cannabis use. Healthy cannabis users did not differ
in white matter volume from either of the schizophrenia
groups. No group differences in cerebellar grey matter or
total volumes could be detected. Interestingly, total
cerebellar volume decreased as a function of duration of
cannabis use in the healthy users, and psychotic symptoms
as well as illness duration correlated with cerebellar mea-
sures differentially between patients with and without
cannabis use. The authors conclude that long-term heavy
cannabis use in healthy individuals is associated with
smaller cerebellar white matter volume similar to that
observed in schizophrenia, but volume reduction is even
more pronounced in patients with schizophrenia using
cannabis.
In a further study including 235 schizophrenia patients
(14 % with comorbid cannabis abuse, 8 % with cannabis
Table 1 continued




sMRI, 1.5 Tesla, 1 mm thickness Cross-
sectional
First-episode schizophrenia with
(N = 6) and without (N = 13)
Cannabis abuse and healthy
controls (N = 19) and healthy
cannabis abusers (N = 17)
FES displayed lower total cerebellar
grey matter than HC, no
difference between FES with and
without cannabis abuse in




sMRI, DTI, VBM Cross-
sectional
EOS with (N = 16) and without
(N = 16) early cannabis abuse
and HC (N = 28)
EOS with cannabis abuse showed
GM density loss in temporal
fusiform gyrus, parahippocampal
gyrus, ventral striatum, right
middle temporal gyrus, insular
cortex, precuneus, right
paracingulate gyrus, dorsolateral
prefrontal cortex, left postcentral
gyrus, lateral occipital cortex and
cerebellum. Similar group
comparison showed decreased
fractional anisotropy (FA) in
particular in brain stem, internal
capsule, corona radiata, superior
and inferior longitudinal







Adolescents with EOS (N = 35),
cannabis abuse (N = 16),
EOS ? cannabis abuse (N = 13),
and healthy controls (HC)
(n = 51)
A significant EOS-by-CUD
interaction was observed. In the
left superior parietal region, both
‘‘pure’’ EOS and ‘‘pure’’ CUD had
smaller grey matter volumes that
were associated with lower
surface area compared with HC. A
similar alteration was observed in
the comorbid group compared
with HC, but there was no
additive volumetric deficit found
in the comorbid group compared
with the separate groups. In the
left thalamus, the comorbid group
had smaller grey matter volumes
compared with the CUD and HC
groups
sMRI structural magnetic resonance imaging, DTI diffusion tensor imaging, ROI region of interest, VBM voxel-based morphometry, GM grey
matter, WM white matter, SUD substance use disorder (substance abuse or dependency), NSUD no substance use disorder (no substance abuse or
dependency), SZ schizophrenia, FES first-episode schizophrenia, EOS early-onset schizophrenia, HC healthy controls
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dependence), patients with marijuana abuse/dependence
had smaller fronto-temporal white matter (WM) volumes
than those without heavy marijuana use [25]. Genotyping
for cannabinoid receptor 1 (CB1/CNR1) demonstrated
significant CNR1 (rs12720071) genotype-by-marijuana-use
interaction effects on WM volumes and neurocognitive
impairment. Furthermore, CNR1 genetic polymorphisms
were associated with WM brain volume variation among
schizophrenia patients. These findings suggest that heavy
cannabis use in the context of specific CNR1 genotypes
may contribute to greater WM volume deficits and cogni-
tive impairment.
Volumetric sMRI studies in recent-onset or first-
episode schizophrenia with comorbid cannabis abuse
Our literature research revealed that most published studies
investigated first-episode or recent-onset schizophrenia
patients in comparison with healthy subjects. However, the
results of these neuroimaging studies are again heteroge-
neous and remain inconclusive.
In one study, patients with recent-onset schizophrenia
(schizoaffective disorder) with comorbid substance abuse
(n = 20, all THC, 7 patients with additional ampheta-
mines/ecstasy consumption, 2 with opiates, 8 with cocaine,
Table 3 Overview of structural magnetic resonance imaging studies in schizophrenia patients (not FES or EOS) with comorbid cannabis abuse









Patients with schizophrenia (N = 17, 47 %
long-term heavy cannabis users), healthy
controls (N = 31, 47 % long-term heavy
cannabis users)
Cerebellar white matter volume was reduced
in cannabis users with and without
schizophrenia compared to healthy non-
users, by 29.7 % and 23.9 %, respectively,
and by 17.7 % in patients without cannabis
use. Healthy cannabis users did not differ in
white matter volume from either of the
schizophrenia groups. There were no group
differences in cerebellar grey matter or total
volumes. Total cerebellar volume decreased










Schizophrenia patients without (N = 183)
and with (N = 52) cannabis abuse
Patients with cannabis abuse/dependence had
smaller fronto-temporal WM volumes than
patients without heavy cannabis use.
Significant genotype-by-cannabis use
interaction effects on WM volumes
sMRI structural magnetic resonance imaging, DTI diffusion tensor imaging, ROI region of interest, VBM voxel-based morphometry, GM grey
matter, WM white matter, SUD substance use disorder (substance abuse or dependency), NSUD no substance use disorder (no substance abuse or
dependency), SZ schizophrenia, FES first-episode schizophrenia, EOS early-onset schizophrenia, HC healthy controls
Table 2 Overview of structural magnetic resonance imaging studies in high-risk or prodromal schizophrenia patients with comorbid cannabis
abuse









Patients with schizophrenia (N = 88), healthy
siblings at higher than average genetic risk for
schizophrenia (N = 98), healthy controls
(N = 87)
Patient group displayed reductions in cortical
thickness for cannabis exposure, a similar pattern








Longitudinal Subjects at high risk for developing schizophrenia
exposed (N = 25) and not exposed (N = 32) to
cannabis in the intervening period of two years
Cannabis exposure was associated with bilateral









Subjects at high risk for developing schizophrenia
(N = 147) and healthy controls (N = 36)
cannabis abuse
Level of cannabis use correlated significantly and
positively with volume increase in the left and
right lateral ventricles and third ventricle
sMRI structural magnetic resonance imaging, DTI diffusion tensor imaging, ROI region of interest, VBM voxel-based morphometry, GM grey
matter, WM white matter, SUD substance use disorder (substance abuse or dependency), NSUD no substance use disorder (no substance abuse or
dependency), SZ schizophrenia, FES first-episode schizophrenia, EOS early-onset schizophrenia, HC healthy controls
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1 with hallucinogens and 2 with alcohol) did not differ
significantly in terms of volumetric morphometry in
temporolimbic regions (superior temporal gyrus, amyg-
dala–hippocampus complex, cingulum) from schizophrenia
patients without previous substance abuse (n = 21) [66].
However, this study did not include a healthy control
group. In a further study of this research group, another
sample suffering from first-episode schizophrenia (n = 47)
and healthy controls (n = 55) underwent MRI scanning,
and volumes of hippocampus, superior temporal gyrus,
prefrontal cortex, internal capsule (ALIC) and the cross-
sectional areas of the corpus callosum were compared
between subgroups of patients with (n = 19) (all cannabis,
4 with additional amphetamines/cocaine) and without
previous substance abuse (n = 28). A significant reduction
in the cross-sectional area of the C 2-segment of the corpus
callosum in the non-abusing patients in comparison with
the patients with previous cannabis abuse could be
observed, suggesting more subtle brain abnormalities in the
group without previous substance abuse [32].
Another study investigating brain volumes in cannabis-
exposed patients with first-episode schizophrenia compared
to non-exposed patients revealed no differences between the
subgroups for total brain volume, total grey and white matter,
ventricles, cerebellum and caudate except a decreased
asymmetry of the lateral ventricles in the cannabis-exposed
patients [7]. In a recent longitudinal study, the same research
group could demonstrate that first-episode schizophrenia
patients with continued use of cannabis (n = 19) showed
increased loss of cerebral grey matter volume and larger
increases in lateral and third ventricle volumes than patients
who did not use cannabis during the follow-up (n = 32) [43].
Nevertheless, brain volumes of schizophrenia patients with
and without cannabis abuse did not differ significantly at the
beginning of the longitudinal study, although it has to be
assumed that the patients abused cannabis several years
before entering the study. The same group of researchers also
performed an analysis of cortical thickness in these patient
groups [44]. At the beginning of the investigation, cortical
thickness did not differ between patients and controls and
between cannabis-using and non-using patients. During the
follow-up period, excessive thinning of the right supple-
mentary motor cortex, inferior frontal cortex, superior tem-
poral gyrus, angular gyrus, occipital and parietal lobe in
patients relative to controls after controlling for the factor
‘‘cannabis use’’ was observed. Patients who used cannabis
showed additional thinning in the left dorsolateral prefrontal
cortex (DLPFC), left anterior cingulate cortex (ACC) and
left occipital lobe as compared to those not using cannabis
during the observation interval.
A further study investigating the volumes of the superior
frontal gyrus, anterior cingulated gyrus and orbital frontal
lobe found less anterior cingulate grey matter in cannabis-
abusing first-episode schizophrenia patients compared with
patients with no history of cannabis abuse and healthy
volunteers [58]. The association between reduced volume
in anterior cingulate gyrus (ACC) and the history of can-
nabis abuse in schizophrenia has been discussed in the
context of a disturbed function of ACC with the conse-
quence of poor decision-making and more compulsive
drive towards drug use as a predisposition to substance
abuse and not as a toxic effect of cannabis itself. This is in
contrast to one study revealing no volumetric differences in
the ACC, the amygdala–hippocampus complex, the STG
and the lateral ventricles between recent-onset schizo-
phrenia patients with and without previous cannabis abuse
[66]. In this study, the patients without previous cannabis
abuse tended to demonstrate more reversed temporal
asymmetry as the non-users. This may be a subtle hint that
the subgroup of cannabis abusers lower their threshold of
psychosis through drug abuse itself and the other subgroup
increases the vulnerability by presenting slightly more
brain abnormalities.
In a more recent voxel-based morphometry (VBM)
study, a decrease in grey matter density in the right posterior
cingulate cortex (PCC) in the subgroup of first-episode
schizophrenia with cannabis abuse was observed compared
to those patients without cannabis abuse [2]. The other
included brain regions with high density of CB1 receptors,
for instance hippocampus, did not differ between these
groups. The authors concluded that cannabis use may be
associated with altered brain structure in particular regions
(in their study PCC) with a high density of CB1 receptors.
A magnetic resonance imaging study focussing on cer-
ebellar grey and white matter in first-episode patients with
and without a history of cannabis use and non-psychiatric
cannabis users revealed a lifetime dose-dependent regional
reduction in grey matter in the right cerebellar lobules and
a tendency for more profound grey matter reduction in
lobule III with younger age at the onset of cannabis use
[11]. First-episode patients had lower total cerebellar grey
matter/total cerebellar volume ratio and marked grey
matter loss in the vermis, pedunculi, flocculi and lobules
compared to pairwise matched healthy controls. This pat-
tern and degree of grey matter loss did not differ from age-
matched first-episode patients with comorbid cannabis use,
indicating only small dose-dependent effects of juvenile
cannabis use on cerebellar neuropathology but no evidence
of an additional effect of cannabis use on cerebellar grey
matter pathology in psychosis.
In an adolescent MRI study, subjects with early-onset
schizophrenia (EOS, n = 35), cannabis use disorder (CUD,
n = 16), comorbid EOS with CUD (n = 13) and healthy
controls (HC) (n = 51) were compared with regard to brain
volume within frontal, temporal, parietal and subcortical
ROIs [29]. If volumetric differences in one ROI were
8 Eur Arch Psychiatry Clin Neurosci (2013) 263:3–13
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identified, cortical thickness and surface area of this ROI
were additionally measured and compared between sub-
groups. The authors found a significant EOS-by-CUD
interaction, in the left superior parietal region; both ‘‘pure’’
EOS and ‘‘pure’’ CUD had smaller grey matter volumes
that were associated with lower surface area compared with
HC. A similar alteration was observed in the comorbid
group compared with HC, but there was no additive vol-
umetric deficit in the comorbid group compared with the
separate groups (EOS and CUD).
In a diffusion tensor imaging (DTI) study, 35 male
recent-onset schizophrenia patients, with and without a
history of cannabis use before the age of 17, and 21 mat-
ched healthy comparison men without illicit drug use were
assessed [40]. In comparison with healthy controls, patients
with cannabis use before the age of 17 showed increased
directional coherence in the bilateral uncinate fasciculus,
anterior internal capsule and frontal WM. These abnor-
malities were absent in patients without cannabis use
before the age of 17, but not related to lifetime doses of
cannabis or other illicit drugs. The authors concluded that
recent-onset schizophrenia patients starting to use cannabis
during early adolescence may represent a subgroup of
schizophrenia patients with increased WM directional
coherence reflecting structural hyperconnectivity. How-
ever, they contrast their results with the fact that in most
DTI studies, schizophrenia patients were associated with
hypoconnectivity [48].
Another study investigated male schizophrenia in early
adolescence patients with regard to abnormalities in WM
structure and integrity using high-resolution structural and
diffusion tensor brain imaging and compared patients who
started a regular use of cannabis (1) before the age of
15 years (early-onset cannabis users, n = 10) or (2) at the
age of 17 years or later (late-onset cannabis users, n = 8),
(3) cannabis-naı¨ve patients (n = 8) and a healthy control
group (n = 10) [12]. Cannabis-naı¨ve patients showed
reduced WM density and reduced fractional anisotropy in
the splenium of the corpus callosum compared with patients
with early-onset cannabis use. In the same brain area,
cannabis-naı¨ve patients showed reduced fractional anisot-
ropy compared with healthy controls, indicating alterations
in fibre density, degree of myelination and WM integrity.
The authors suggest that the age of onset of cannabis use is
not an identifying characteristic for WM abnormalities in
schizophrenia patients and that cannabis-naı¨ve schizophre-
nia patients may have a more vulnerable brain structure
which may responsible for the onset of psychosis.
In a further VBM and DTI study comparing patients
with adolescent-onset schizophrenia (AOS) with early
cannabis use (more than 3 times/week for at least
6 months) (n = 16) to AOS without cannabis use (n = 16)
and healthy adolescents (n = 28), those with cannabis
abuse showed increased GM density loss in temporal
fusiform gyrus, parahippocampal gyrus, ventral striatum,
right middle temporal gyrus, insular cortex, precuneus,
right paracingulate gyrus, dorsolateral prefrontal cortex,
left postcentral gyrus, lateral occipital cortex and cerebel-
lum [26]. In addition, cannabis-abusing AOS demonstrated
decreased fractional anisotropy (FA) in particular in brain
stem, internal capsule, corona radiata, superior and inferior
longitudinal fasciculus compared to those without cannabis
abuse. Interestingly, there were no cognitive differences
between patients with and without cannabis abuse, but both
subgroups impaired relative to controls.
Volumetric sMRI studies in high-risk or prodromal
schizophrenia patients with comorbid cannabis abuse
Our search revealed three studies accessing cortical vol-
umes in high-risk subjects and pointing towards an effect
of cannabis in this population. In the Edinburgh high-risk
study (EHRS), individuals at high familial risk of schizo-
phrenia were scanned at the point of entry into the study
and approximately 2 years later. This study focussed on
volumetric measurements of the thalamus and the amyg-
dala–hippocampus complex. Compared to high-risk indi-
viduals not exposed to cannabis (n = 32), subjects with
cannabis consumption (n = 25) revealed a bilateral tha-
lamic volume loss over time [62].
A study investigating cortical thickness in several brain
regions in schizophrenia patients (n = 88), their healthy
siblings (n = 98) and healthy control subjects (n = 87)
showed a significant interaction of cortical thickness with
cannabis use in the patient and the sibling groups, but not in
the healthy control group. This finding displays stronger
reductions in cortical thickness in subjects with cannabis use
in the patient and genetic high-risk group [22]. These results
allowed the authors to hypothesize that gene–environment
interactions may underlie this type of brain alteration
observed in patients with schizophrenia and their relatives.
In another study including 147 at-risk subjects and 36
healthy controls, a dose-dependent increase in ventricular
volume was associated with alcohol and cannabis use [61].
Additionally, alcohol and cannabis abuse were associated
with an increased subsequent risk of schizophrenia. This
may provide evidence that the use of cannabis or alcohol
by people at high genetic risk of schizophrenia is associ-
ated with brain abnormalities (ventricular volume increase)
and later risk of psychosis.
Discussion
We reviewed structural MRI studies in schizophrenia
patients and at-risk subjects with comorbid cannabis abuse
Eur Arch Psychiatry Clin Neurosci (2013) 263:3–13 9
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to elucidate the interplay between cannabis consumption,
schizophrenia and volumetric brain alterations. The results
of the identified neuroimaging studies are heterogeneous
and inconclusive, which may be due to several reasons.
First, we should keep in mind that the heterogeneity of
the definition of the regional volume (ROIs) boundaries,
differences in MRI techniques and volume extractions in
previous studies make it difficult to compare volumetric
measurements. Apart from selection bias of study samples,
there seems to be a systematically difference when com-
paring volume data using VBM or the region of interest
(ROI) method.
Secondly, selection of study samples may have an
enormous influence on the reported results taking the
mainly small numbers of patients and healthy subjects into
account. For instance, decreases in grey and WM volume
over time may be related to the duration, type and cumu-
lative dose of antipsychotic medication patients received
[24].
Most studies are cross-sectional and include recent-
onset psychosis or first-episode schizophrenia patients,
comparing those with and without comorbid cannabis
abuse at a certain time point in their disease course. To
evaluate the impact of comorbid cannabis abuse over time
and to make a statement about a possible neurodegenera-
tive or even toxic process, a within-subject comparison in a
longitudinal design (e.g., prodromal state, first-episode
state, recent-onset state, chronic state) would be an appli-
cable way. Another important issue is the impact of anti-
psychotic medication and of the disease course. Although
one could assume that the influence of antipsychotic
medication in first-episode patients is not as strong as in
chronic patients, other parameters like the duration of ill-
ness (DUI) and the duration of psychosis (DUP) may have
a significant influence on brain volume more relevant than
previous cannabis abuse.
From this point of view, the longitudinal studies of Rais
et al. [43] are of certain interest. While finding no signifi-
cant differences at study entry between subgroups, the
authors could demonstrate an increased loss of cerebral
grey matter, a larger increase in ventricle volume and an
increased thinning of cortical thickness in the left DLPFC,
left ACC and left occipital lobe in those first-episode
patients who continued their cannabis abuse. This implies
an additional influence of cannabis on brain structures apart
from schizophrenia itself. A very interesting work analysed
brain volumes of 211 schizophrenia patients in a longitu-
dinal study design with a long follow-up period (follow-up
scan was performed after 2, 5 and 9 years and every
3 years thereafter) [24]. The authors showed that antipsy-
chotic treatment was associated with the strongest reduc-
tion in grey matter volumes, whereas illness severity had
only little effect [24]. With regard to this review and our
hypothesis, it is surprising that alcohol and illicit drug
misuse (including cannabis abuse) had only an effect on
lateral ventricles and on cerebellar volumes, but not on
total brain tissue and hippocampal structures. However,
after correction for other variables (antipsychotic medica-
tion, illness duration, illness severity) alcohol/illicit drug
misuse, the effects did not remain significant [24]. There-
fore, the main finding of this largest longitudinal study
investigating brain volumes in schizophrenia patients is
that the relationship between antipsychotic treatment and
decrease in brain volumes in schizophrenia patients over
time remains significant, even after correction for alcohol/
illicit drug misuse and for illness severity/duration [24],
[30]. Many studies include comorbid patients consuming
other substances than cannabis, for example, ampheta-
mines, cocaine and sometimes alcohol, making it difficult
to focus on the effect of cannabis alone. Although the
numbers of these patients are small, an influence of the
additional consumed drugs could not be definitely exclu-
ded, especially elevated alcohol consumption is known to
reduce grey matter volume [33].
Some studies of recent-onset psychosis patients include
subjects with schizoaffective disorder, which may also
influence volumetric measurement because these patients
show a different disease course, may display minor cog-
nitive dysfunction and have a shorter DUI than schizo-
phrenia patients [66].
The MR studies of high-risk subjects suggest there is an
additional effect of cannabis use on brain structure (e.g.,
reduction in thalamic volume) in this highly vulnerable pop-
ulation for the development of later schizophrenia. But the
number of the available studies (n = 3) is too small to allow
further conclusions, and the results need to be replicated.
Influence of cannabis on brain structure
When discussing the influence of cannabis on brain struc-
ture in schizophrenia patients, it is important to have a look
on the influence of cannabis on brain structure itself,
shortly summarizing the results of neuroimaging studies in
cannabis abusers without schizophrenia. Therefore, it is
noteworthy that the structural neuroimaging studies in
cannabis abusers without schizophrenia revealed conflict-
ing results [42]. For instance, while two studies could not
demonstrate an influence of cannabis on brain morphology,
especially on hippocampus, compared to controls [5, 60], a
third study found lower grey matter volumes in the right
parahippocampal region, lower WM density in the left
parietal region as well as increased volumes of bilateral
fusiform gyrus, right thalamus and left parahippocampal
region in the group of chronic cannabis users [35]. Other
investigators detected only less frontal white matter vol-
ume percentage in the group of substance abusers
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(cannabis, opiates and cocaine) compared to healthy con-
trols [47]. Another study without healthy control group
revealed a significant correlation between age of first use
and decreased total brain volume [63]. Subjects who started
using marijuana before the age of 17, compared to those
who started later, revealed smaller whole brain and per cent
cortical grey matter and larger per cent WM volumes [63].
Although no data regarding the amount of cannabis con-
sumption were given in most studies, one could speculate
whether differences in cannabis use are responsible for the
conflicting results. Most studies did not differentiate
between different types of cannabis or the average amount of
cannabis per use. The content of psychoactive tetrahydro-
cannabinol varies widely across different types of cannabis
[41]. This important limitation complicates the exploration
of dose–response relationships in the cited studies.
Conclusions
In summary, there is some evidence that chronic cannabis
abuse could alter brain morphology in schizophrenia in
patients continuing their cannabis consumption, but there is
no convincing evidence that this alteration takes place
before the onset of schizophrenia when looking at first-
episode patients. There is some weak evidence that can-
nabis abuse could affect brain structures in high-risk sub-
jects, but replication of these findings is needed. However,
even if previous cannabis substance abuse seems not to
lead to pronounced structural brain abnormalities in
schizophrenia [66], it may cause functional changes on
cortical inhibition processes and synaptic transmission
involving mainly the GABAergic, glutamatergic and
dopaminergic system in schizophrenia patients and unaf-
fected cannabis consumers [64]. This effect of cannabis on
distinct brain functions including regulation of cortical
excitability [17] could be the reason why cannabis con-
sumption is associated with a higher risk of developing
schizophrenia and not primarily pronounced structural
brain alterations. It is conceivable that this disinhibition
following cannabis abuse might lead to a consecutive
neurotoxicity leading to subtle alterations in brain struc-
tures. Well-designed studies and the combination of brain
imaging and neurophysiological techniques will open the
doors to new possibilities for the investigation of these
important questions.
Acknowledgments B.M. performed the literature search, prepared
the first draft, works on the manuscript and prepared the final version.
A.H., P.F., P.F-P and T.W. worked on the manuscript and prepared
the final version.
Conflict of interest The authors declare no conflict of interest
regarding the presented work.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Andreasen NC (2000) Schizophrenia: the fundamental questions.
Brain Res Brain Res Rev 31:106–112
2. Bangalore SS, Prasad KM, Montrose DM, Goradia DD, Diwad-
kar VA, Keshavan MS (2008) Cannabis use and brain structural
alterations in first episode schizophrenia–—a region of interest,
voxel based morphometric study. Schizophr Res 99:1–6
3. Barta PE, Pearlson GD, Powers RE, Richards SS, Tune LE
(1990) Auditory hallucinations and smaller superior temporal
gyral volume in schizophrenia. Am J Psychiatry 147:1457–1462
4. Bersani G, Orlandi V, Kotzalidis GD, Pancheri P (2002) Cannabis
and schizophrenia: impact on onset, course, psychopathology and
outcomes. Eur Arch Psychiatry Clin Neurosci 252:86–92
5. Block RI, O’Leary DS, Ehrhardt JC, Augustinack JC, Ghoneim
MM, Arndt S, Hall JA (2000) Effects of frequent marijuana use on
brain tissue volume and composition. NeuroReport 11:491–496
6. Buhler B, Hambrecht M, Loffler W, an der Heiden W, Hafner H
(2002) Precipitation and determination of the onset and course of
schizophrenia by substance abuse—a retrospective and prospec-
tive study of 232 population-based first illness episodes. Schiz-
ophr Res 54:243–251
7. Cahn W, Hulshoff Pol HE, Caspers E, van Haren NE, Schnack
HG, Kahn RS (2004) Cannabis and brain morphology in recent-
onset schizophrenia. Schizophr Res 67:305–307
8. Cantor-Graae E, Nordstrom LG, McNeil TF (2001) Substance
abuse in schizophrenia: a review of the literature and a study of
correlates in Sweden. Schizophr Res 48:69–82
9. Caspari D (1999) Cannabis and schizophrenia: results of a fol-
low-up study. Eur Arch Psychiatry Clin Neurosci 249:45–49
10. Cohen LJ, Test MA, Brown RL (1990) Suicide and schizophre-
nia: data from a prospective community treatment study. Am J
Psychiatry 147:602–607
11. Cohen M, Rasser PE, Peck G, Carr VJ, Ward PB, Thompson PM,
Johnston P, Baker A, Schall U (2011) Cerebellar grey-matter
deficits, cannabis use and first-episode schizophrenia in adoles-
cents and young adults. Int J Neuropsychopharmacol. May
4:1–11 [Epub ahead of print]
12. Dekker N, Schmitz N, Peters BD, van Amelsvoort TA, Linszen
DH, de Haan L (2010) Cannabis use and callosal white matter
structure and integrity in recent-onset schizophrenia. Psychiatry
Res 181:51–56
13. Dixon L, Haas G, Weiden PJ, Sweeney J, Frances AJ (1991)
Drug abuse in schizophrenic patients: clinical correlates and
reasons for use. Am J Psychiatry 148:224–230
14. Ellison-Wright I, Glahn DC, Laird AR, Thelen SM, Bullmore E
(2008) The anatomy of first-episode and chronic schizophrenia:
an anatomical likelihood estimation meta-analysis. Am J Psy-
chiatry 165:1015–1023
15. Ettinger U, Chitnis XA, Kumari V, Fannon DG, Sumich AL,
O’Ceallaigh S, Doku VC, Sharma T (2001) Magnetic resonance
imaging of the thalamus in first-episode psychosis. Am J Psy-
chiatry 158:116–118
16. Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF,
Moller HJ (2005) World federation of societies of biological
psychiatry (wfsbp) guidelines for biological treatment of
schizophrenia, part 1: acute treatment of schizophrenia. World J
Biol Psychiatry 6:132–191
Eur Arch Psychiatry Clin Neurosci (2013) 263:3–13 11
123
17. Fitzgerald PB, Williams S, Daskalakis ZJ (2009) A transcranial
magnetic stimulation study of the effects of cannabis use on
motor cortical inhibition and excitability. Neuropsychopharma-
cology 34:2368–2375
18. Fornito A, Yucel M, Patti J, Wood SJ, Pantelis C (2009) Mapping
grey matter reductions in schizophrenia: an anatomical likelihood
estimation analysis of voxel-based morphometry studies. Schiz-
ophr Res 108:104–113
19. Gilbert AR, Rosenberg DR, Harenski K, Spencer S, Sweeney JA,
Keshavan MS (2001) Thalamic volumes in patients with first-
episode schizophrenia. Am J Psychiatry 158:618–624
20. Gur RE, Cowell P, Turetsky BI, Gallacher F, Cannon T, Bilker
W, Gur RC (1998) A follow-up magnetic resonance imaging
study of schizophrenia. Relationship of neuroanatomical changes
to clinical and neurobehavioral measures. Arch Gen Psychiatry
55:145–152
21. Gur RE, Turetsky BI, Cowell PE, Finkelman C, Maany V,
Grossman RI, Arnold SE, Bilker WB, Gur RC (2000) Temp-
orolimbic volume reductions in schizophrenia. Arch Gen Psy-
chiatry 57:769–775
22. Habets P, Marcelis M, Gronenschild E, Drukker M, van Os J
(2011) Reduced cortical thickness as an outcome of differential
sensitivity to environmental risks in schizophrenia. Biol Psychi-
atry 69:487–494
23. Haywood TW, Kravitz HM, Grossman LS, Cavanaugh JL Jr,
Davis JM, Lewis DA (1995) Predicting the ‘‘revolving door’’
phenomenon among patients with schizophrenic, schizoaffective,
and affective disorders. Am J Psychiatry 152:856–861
24. Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V (2011)
Long-term antipsychotic treatment and brain volumes: a longi-
tudinal study of first-episode schizophrenia. Arch Gen Psychiatry
68:128–137
25. Ho BC, Wassink TH, Ziebell S, Andreasen NC (2011) Cannab-
inoid receptor 1 gene polymorphisms and marijuana misuse
interactions on white matter and cognitive deficits in schizo-
phrenia. Schizophr Res 128:66–75
26. James A, Hough M, James S, Winmill L, Burge L, Nijhawan S,
Matthews PM, Zarei M (2011) Greater white and grey matter
changes associated with early cannabis use in adolescent-onset
schizophrenia (AOS). Schizophr Res 128:91–97
27. Joyal CC, Laakso MP, Tiihonen J, Syvalahti E, Vilkman H, Laakso
A, Alakare B, Rakkolainen V, Salokangas RK, Hietala J (2002) A
volumetric mri study of the entorhinal cortex in first episode neu-
roleptic-naive schizophrenia. Biol Psychiatry 51:1005–1007
28. Kovasznay B, Fleischer J, Tanenberg-Karant M, Jandorf L,
Miller AD, Bromet E (1997) Substance use disorder and the early
course of illness in schizophrenia and affective psychosis.
Schizophr Bull 23:195–201
29. Kumra S, Robinson P, Tambyraja R, Jensen D, Schimunek C,
Houri A, Reis T, Lim K (2012) Parietal lobe volume deficits in
adolescents with schizophrenia and adolescents with cannabis use
disorders. J Am Acad Child Adolesc Psychiatry 51:171–180
30. Lewis DA (2011) Antipsychotic medications and brain volume:
do we have cause for concern? Arch Gen Psychiatry 68:126–127
31. Linszen DH, Dingemans PM, Lenior ME (1994) Cannabis abuse
and the course of recent-onset schizophrenic disorders. Arch Gen
Psychiatry 51:273–279
32. Malchow B, Gruber O, Scherk H, Reith W, Schneider Axmann T,
Falkai P, Wobrock T (2008) Differences in corpus callosum size
between first-episode schizophrenia patients with and without
cannabis abuse. Eur Arch Psychiatry Clin Neurosci 258:1
33. Mathalon DH, Pfefferbaum A, Lim KO, Rosenbloom MJ, Sullivan
EV (2003) Compounded brain volume deficits in schizophrenia-
alcoholism comorbidity. Arch Gen Psychiatry 60:245–252
34. Matheson SL, Shepherd AM, Laurens KR, Carr VJ (2011) A
systematic meta-review grading the evidence for non-genetic risk
factors and putative antecedents of schizophrenia. Schizophr Res
133:133–142
35. Matochik JA, Eldreth DA, Cadet JL, Bolla KI (2005) Altered
brain tissue composition in heavy marijuana users. Drug alcohol
dependence 77:23–30
36. Mueser KT, Drake RE, Wallach MA (1998) Dual diagnosis: a
review of etiological theories. Addict Behav 23:717–734
37. Mueser KT, Yarnold PR, Levinson DF, Singh H, Bellack AS,
Kee K, Morrison RL, Yadalam KG (1990) Prevalence of sub-
stance abuse in schizophrenia: demographic and clinical corre-
lates. Schizophr Bull 16:31–56
38. Nelson MD, Saykin AJ, Flashman LA, Riordan HJ (1998) Hip-
pocampal volume reduction in schizophrenia as assessed by
magnetic resonance imaging: a meta-analytic study. Arch Gen
Psychiatry 55:433–440
39. Peralta V, Cuesta MJ (1992) Influence of cannabis abuse on
schizophrenic psychopathology. Acta Psychiatr Scand 85:127–130
40. Peters BD, de Haan L, Vlieger EJ, Majoie CB, den Heeten GJ,
Linszen DH (2009) Recent-onset schizophrenia and adolescent
cannabis use: mri evidence for structural hyper connectivity?
Psychopharmacol Bull 42:75–88
41. Potter DJ, Clark P, Brown MB (2008) Potency of delta 9-THC and
other cannabinoids in cannabis in England in 2005: implications for
psychoactivity and pharmacology. J Forensic Sci 53:90–94
42. Quickfall J, Crockford D (2006) Brain neuroimaging in cannabis
use: a review. J Neuropsychiatry Clin Neurosci 18:318–332
43. Rais M, Cahn W, Van Haren N, Schnack H, Caspers E, Pol
Hulshoff H, Kahn R (2008) Excessive brain volume loss over
time in cannabis-using first-episode schizophrenia patients. Am J
Psychiatry 165:490–496
44. Rais M, van Haren NE, Cahn W, Schnack HG, Lepage C, Collins
L, Evans AC, Pol Hulshoff HE, Kahn RS (2010) Cannabis use
and progressive cortical thickness loss in areas rich in CB1
receptors during the first five years of schizophrenia. Eur Neu-
ropsychopharmacol 20:855–865
45. Rasanen P, Tiihonen J, Isohanni M, Rantakallio P, Lehtonen J,
Moring J (1998) Schizophrenia, alcohol abuse, and violent
behavior: a 26-year followup study of an unselected birth cohort.
Schizophr Bull 24:437–441
46. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL,
Goodwin FK (1990) Comorbidity of mental disorders with
alcohol and other drug abuse. Results from the epidemiologic
catchment area (ECA) study. JAMA 264:2511–2518
47. Schlaepfer TE, Lancaster E, Heidbreder R, Strain EC, Kosel M,
Fisch HU, Pearlson GD (2006) Decreased frontal white-matter
volume in chronic substance abuse. Int J Neuropsychopharmacol
9:147–153
48. Schmitt A, Hasan A, Gruber O, Falkai P (2011) Schizophrenia as
a disorder of disconnectivity. Eur Arch Psychiatry Clin Neurosci
261(Suppl 2):S150–S154. doi:10.1007/s00406-011-0242-2
49. Seibyl JP, Satel SL, Anthony D, Southwick SM, Krystal JH,
Charney DS (1993) Effects of cocaine on hospital course in
schizophrenia. J Nerv Ment Dis 181:31–37
50. Shenton ME, Dickey CC, Frumin M, McCarley RW (2001) A
review of mri findings in schizophrenia. Schizophr Res 49:1–52
51. Shenton ME, Kikinis R, Jolesz FA, Pollak SD, LeMay M, Wible
CG, Hokama H, Martin J, Metcalf D, Coleman M et al (1992)
Abnormalities of the left temporal lobe and thought disorder in
schizophrenia. A quantitative magnetic resonance imaging study.
N Engl J Med 327:604–612
52. Solowij N, Yucel M, Respondek C, Whittle S, Lindsay E, Pant-
elis C, Lubman DI (2011) Cerebellar white-matter changes in
cannabis users with and without schizophrenia. Psychol Med
41:2349–2359
53. Soyka M, Albus M, Immler B, Kathmann N, Hippius H (2001)
Psychopathology in dual diagnosis and non-addicted
12 Eur Arch Psychiatry Clin Neurosci (2013) 263:3–13
123
schizophrenics–are there differences? Eur Arch Psychiatry Clin
Neurosci 251:232–238
54. Soyka M, Albus M, Kathmann N, Finelli A, Hofstetter S, Holz-
bach R, Immler B, Sand P (1993) Prevalence of alcohol and drug
abuse in schizophrenic inpatients. Eur Arch Psychiatry Clin
Neurosci 242:362–372
55. Soyka M, Kranzler HR, Berglund M, Gorelick D, Hesselbrock V,
Johnson BA, Moller HJ (2008) World federation of societies of
biological psychiatry (WFSBP) guidelines for biological treat-
ment of substance use and related disorders, part 1: alcoholism.
World J Biol Psychiatry 9:6–23
56. Swofford CD, Kasckow JW, Scheller-Gilkey G, Inderbitzin LB
(1996) Substance use: a powerful predictor of relapse in schizo-
phrenia. Schizophr Res 20:145–151
57. Szeszko PR, Goldberg E, Gunduz-Bruce H, Ashtari M, Robinson
D, Malhotra AK, Lencz T, Bates J, Crandall DT, Kane JM, Bilder
RM (2003) Smaller anterior hippocampal formation volume in
antipsychotic-naive patients with first-episode schizophrenia. Am
J Psychiatry 160:2190–2197
58. Szeszko PR, Robinson DG, Sevy S, Kumra S, Rupp CI, Betensky
JD, Lencz T, Ashtari M, Kane JM, Malhotra AK, Gunduz-Bruce
H, Napolitano B, Bilder RM (2007) Anterior cingulate grey-
matter deficits and cannabis use in first-episode schizophrenia. Br
J Psychiatry 190:230–236
59. Torrey EF (2002) Studies of individuals with schizophrenia never
treated with antipsychotic medications: a review. Schizophr Res
58:101–115
60. Tzilos GK, Cintron CB, Wood JB, Simpson NS, Young AD, Pope
HG Jr, Yurgelun-Todd DA (2005) Lack of hippocampal volume
change in long-term heavy cannabis users. Am J Addict 14:64–72
61. Welch KA, McIntosh AM, Job DE, Whalley HC, Moorhead TW,
Hall J, Owens DG, Lawrie SM, Johnstone EC (2011) The impact
of substance use on brain structure in people at high risk of
developing schizophrenia. Schizophr Bull 37:1066–1076
62. Welch KA, Stanfield AC, McIntosh AM, Whalley HC, Job DE,
Moorhead TW, Owens DG, Lawrie SM, Johnstone EC (2011)
Impact of cannabis use on thalamic volume in people at familial
high risk of schizophrenia. Br J Psychiatry
63. Wilson W, Mathew R, Turkington T, Hawk T, Coleman RE,
Provenzale J (2000) Brain morphological changes and early
marijuana use: a magnetic resonance and positron emission
tomography study. J Addict Dis 19:1–22
64. Wobrock T, Hasan A, Malchow B, Wolff-Menzler C, Guse B, Lang
N, Schneider-Axmann T, Ecker UK, Falkai P (2010) Increased
cortical inhibition deficits in first-episode schizophrenia with
comorbid cannabis abuse. Psychopharmacology 208:353–363
65. Wobrock T, Pajonk FG, D’Amelio R, Falkai P (2005) Schizo-
phrenia and addiction. PsychoNeuro 31:433–440
66. Wobrock T, Sittinger H, Behrendt B, D’Amelio R, Falkai P
(2009) Comorbid substance abuse and brain morphology in
recent-onset psychosis. Eur Arch Psychiatry Clin Neurosci
259:28–36
67. Wobrock T, Sittinger H, Behrendt B, D’Amelio R, Falkai P,
Caspari D (2007) Comorbid substance abuse and neurocognitive
function in recent-onset schizophrenia. Eur Arch Psychiatry Clin
Neurosci 257:203–210
68. Wright IC, Rabe-Hesketh S, Woodruff PW, David AS, Murray
RM, Bullmore ET (2000) Meta-analysis of regional brain vol-
umes in schizophrenia. Am J Psychiatry 157:16–25
Eur Arch Psychiatry Clin Neurosci (2013) 263:3–13 13
123
